The role of cytokines in chlamydial infections

Current Opinion in Infectious Diseases

Volumn 9, Issue 3, 1996, Pages 150-155

  Malinverni, Raffaele ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE;

ATHEROSCLEROSIS; CELL CULTURE; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; EXPERIMENTAL ANIMAL; FEMALE INFERTILITY; HUMAN; IMMUNOPATHOLOGY; NONHUMAN; PERSISTENT INFECTION; SHORT SURVEY; TRACHOMA;

EID: 0030056551     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199606000-00004     Document Type: Short Survey

References (36)

1. Beatty WL, Morrison RP, Byrne GI: Persistent Chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis. Microbiol Rev 1994, 58:685-699. An extensive and excellent review of chlamydial persistence with a discussion on the possible mechanism of persistence and on correlations between data derived from cell culture systems and events occurring in natural infections.
2. Beatty WL, Byrne GI, Morrison RP: Morphologic and antigenic characterization of interferon-γ-mediated persistent Chlamydia trachomatis infection in vitro. Proc Natl Acad Sci USA 1993, 90:3998-4002.
3. Beatty WL, Morrison RP, Byrne GI: Reactivation of persistent Chlamydia trachomatis infection in cell culture. Infect Immun 1995, 63:199-205. An extension of the previous study investigating the events occurring during reactivation of infectious Chlamydiae from persistently infected cell cultures. After the transfer of persistent organisms to an IFN-γ-free medium recovery of infectivity, reorganization of aberrant organisms into morphologically typical organisms and expression of characteristic structural proteins were observed. Persistent organisms maintained viability for several weeks and reversibility of persistence into a normal developmental cycle was demonstrated.
4. Campbell LA, Patton DL, Moore DE, Cappuccio AL, Mudler BA, Wang S: Detection of Chlamydia trachomatis deoxyribonucleic acid in women with tubal infertility. Fertil Steril 1993, 59:45-50.
5. Stevens DL: Cytokines: an updated compendium. Curr Opin Infect Dis 1995, 8:175-180.
6. Pfeffer korn ER: Interferon-γ blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cell to degrade tryptophan. Proc Natl Acad Sci USA 1984, 81:908-912.
7. Carlin JM, Borden EM, Byrne GI: Interferon-induced indoleamine 2,3-dioxygenase activity inhibits Chlamydia psittaci replication in human macrophages. J Interferon Res 1989, 9:329-337.
8. Thomas SM, Garrity LF, Brandt CR, Schobert CS, Feng GS, Taylor MW, Carlin JM, Byrne GI: IFN-gamma-mediated antimicrobial response. Indoleamine 2,3-dioxygenase-deficient mutant host cells no longer inhibit intracellular Chlamydia spp. or Toxoplasma growth. J Immunol 1993, 150:5529-5534.
9. Beatty WL, Belanger TA, Desai AA, Morrison RP, Byrne GI: Tryptophan depletion as a mechanism of gamma interferon-mediated chlamydial persistence. Infect Immun 1994, 62:3705-3711. Important studies aimed at investigating whether the mechanism inducing chlamydial persistence is similar to that reported to inhibit chlamydial growth. Several experiments using infected cells cultured in medium with incremental levels of exogenous tryptophan indicated that persistence was induced by reducing the amount of tryptophan, and studies in a mutant cell line responsive to IFN-γ but IDO-deficient indicated that IDO-mediated trypto-phan catabolism was the mechanism by which IFN-γ mediates persistence.
10. Meyer KC, Cornwell R, Carlin JM, Powers C, Irizarry A, Byrne GI, Boden EC: Effects of interferons beta or gamma on neopterin biosynthesis and tryptophan degradation by human alveolar macrophages in vitro: synergy with lipopolysaccharide. Am J Respir Cell Mol Biol 1992, 6:639-646.
11. Paguirigan AM, Byrne GI, Becht S. Carlin JM: Cytokine-mediated indoleamine 2,3-dioxygenase induction in response to Chlamydia infection in human macrophage cultures. Infect Immun 1994, 62:1131-1136.
12. Ingalls RR, Rice PA, Qureshi N, Takayama K, Lin JS, Golenbock DT: The inflammatory cytokine response to Chlamydia trachomatis infection is endotoxin mediated. Infect Immun 1995, 63:3125-3130. An important study focussing on the molecular characterization of the acute immune response to Chlamydiae, with particular regard to the role of chlamydial LPS. Biological activity was assayed by measurements of TNF-α release from whole blood and by induction of translocation of nuclear factor κB in a hamster fibroblast cell line transfected with LPS-receptor CD14. In both assays C. trachomatis LPS was less potent than LPS from S. minnesota and Neisseria gonorrhoeae. Specific LPS antagonists were able to inhibit the activity of C. trachomatis LPS completely.
13. Carlin JM, Weller JB: Potentiation of interferon-mediated inhibition of Chlamydia infection by interleukin-1 in human macrophage cultures. Infect Immun 1995, 63:1870-1875.
14. Magee DM, Smith JG, Bleicker CH, Carter CJ, Bonewald LF, Schachter J, Williams DM: Chlamydia trachomatis pneumonia induces in-vivo production of interleukin-1 and -6. Infect Immun 1992, 60:1217-1220.
15. 2 production by human synovial cells. J Clin Invest 1986, 77:645-648.
16. Summersgill JT, Sahney NN, Gaydos CA, Quinn TC, Ramirez JA: Inhibition of Chlamydia pneumoniae growth in HEp-2 cells pretreated with gamma-interferon and tumour necrosis factor-alpha. Infect Immun 1995, 63:2801-2803.
17. Rothermel CD, Rubin BY, Jaffe EA, Murray HW: Oxygen-dependent inhibition of intracellular Chlamydia psittaci growth by human monocytes and interferon-γ-activated macrophages. J Immunol 1986, 137:689-692.
18. Shemer-Avni Y, Wallach D, Sarov I: Inhibition of Chlamydia trachomatis growth by recombinant tumour necrosis factor. Infect Immun 1988, 56:2503-2506.
19. Campbell LA, O'Brien ER, Cappuccio AL, Kuo CC, Wang S-P, Stewart D, Patton DL, Cummings PK, Grayston JT: Detection of Chlamydia pneumoniae TWAR in human coronary atherectomy tissues. J Infect Dis 1995, 172:585-588. Thirty-eight fresh-tissue specimens from patients with coronary artery lesions treated by bidirectional coronary atherectomy were tested for the presence of C. pneumoniae by immunocytochemical stain and polymerase chain reaction. C. pneumoniae was detected in 20 out of 38 specimens and was localized to macrophages by cell identity markers. The organism appeared to be detected more frequently in tissues from restenosis rather than in primary lesions.
20. Kuo CC, Grayston JT, Campbell LA, Goo YA, Wissler RW, Benditt E: Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15-35 years old). Proc Natl Acad Sci USA 1995, 92:6911-6914. An age-matched morphological study investigating autopsy tissue of coronary arteries from young persons with early atherosclerosis. Immunochemistry and polymerase chain reaction were used to detect C. pneumoniae and cytomegalovirus in a left anterior descending coronary artery sample. C. pneumoniae was detected in 86% of atheroma samples, 18% of samples with intimai thickening and none of the normal-appearing coronary samples. Cytomegalovirus was detected rarely in diseased as well as in normal samples. This study further strengthens the association between C. pneumoniae and coronary atherosclerosis.
21. Byrne GI, Grubbs B, Dickey TJ, Schachter J, Williams DM: Interferon in recovery from pneumonia due to Chlamydia trachomatis in the mouse. J Infect Dis 1989, 156:993-994.
22. Williams DM, Byrne GI, Grubbs B, Marshal TJ, Schachter J: Role in vivo for gamma interferon in control of pneumonia caused by Chlamydia trachomatis in mice. Infect Immun 1988, 56:3004-3006.
23. Williams DM, Grubbs BG, Schachter J, Magee DM: Gamma interferon levels during Chlamydia trachomatis pneumonia in mice. Infect Immun 1993, 61:3556-3558.
24. Rank RG, Ramsey KH, Pack EA, Williams DM. Effect of gamma interferon on resolution of murine chlamydial genital infection. Infect Immun 1992, 60:4427-4429.
25. McCafferty MC, Maley SW, Entrican G, Buxton D: The importance of interferon-gamma in an early infection of Chlamydia psittaci in mice. Immunology 1994, 81:631-636.
26. Zhong G, Peterson EM, Czarniecki CW, Schreiber RD, De la Maza LM: Role of endogenous gamma interferon in host defence against Chlamydia trachomatis Infections. Infect Immun 1989, 57:152-157.
27. Williams DM, Bonewald LF, Roodman GD, Byrne GI, Magee DM, Schachter J: Tumor necrosis factor alpha is a cytotoxin induced by murine Chlamydia trachomatis infection. Infect Immun 1989, 57:1351-1355.
28. Darville T, Laffoon KK, Kishen LR, Rank RG: Tumour necrosis factor alpha activity in genital tract secretions of guinea pigs infected with Chlamydiae. Infect Immun 1995, 63:4675-4681. These studies were aimed at elucidating the stimuli that initiate inflammation after chlamydial infection with guinea pig inclusion conjunctivitis agent in a genital tract infection model of the guinea pig. Cytotoxicity assays for TNF performed on genital tract secretions showed high levels of TNF early during primary infection, paralleling marked neutrophil influx. Significantly lower levels of TNF were detected during challenge infection.
29. Toth MJ, Jeremias J, Ledger WJ, Wibkin SS: In-vivo tumour necrosis factor production in women with salpingitis. Surg Gynecol Obstet 1992, 174:359-362.
30. Cotter TW, Meng Q, Shen ZL, Zhang YX, Su H, Caldwell HD: Protective efficacy of major outer membrane protein-specific immunoglobulin (IgA) and IgG monoclonal antibodies in a murine model of Chlamydia trachomatis genital tract infection. Infect Immun 1995, 63:4704-4714. A series of outstanding experiments providing the first evidence that delivery of Chlamydia-specific antibody from submucosae into secretions can protect from chlamydial infection in vivo. The authors used hybridoma tumour implantation in mice to deliver MoPn-specific antibody before vaginal challenge with the MoPn agent. IgG and IgA reduced lower genital tract infection. Whereas this effect was marginal and was overwhelmed by higher chlamydial challenge doses, the effect on ascending chlamydial infection and upper genital tract pathology was more pronounced.
31. Igietseme JU, Ramsey KH, Magee DM, Williams DM, Kincy TJ, Rank RG: Resolution of murine chlamydial genital infection by the adoptive transfer of a biovar-specific, Th1 lymphocyte clone. Reg Immunol 1993, 5:317-324.
32. Magee DM, Williams DM, Smith JG, Bleicker CA, Grubbs BG, Schachter J, Rank RG: Role of CD8 T cells in primary Chlamydia infection. Infect Immun 1995, 63:516-521.
33. Kincy Cain T, Rank RG: Local Th1-like responses are induced by intravaginal infection of mice with the mouse pneumonitis biovar of Chlamydia trachomatis. Infect Immun 1995, 63:1784-1789.
34. Morrison RP, Feilzer K, Tumas DB: Gene knockout mice establish a primary protective role for major histocompatibility complex class II-restricted responses in Chlamydia trachomatis genital tract infection. Infect Immun 1995, 63:4661-4668. Mice with disrupted β-2 microglobulin, I-A or CD4 genes were used to study the course of genital tract infection caused by the MoPn agent. MHC class II -/- mice failed to resolve infection, and CD4 -/- showed slower resolution when compared with controls or β-2 microglobulin -/- mice which showed a similar course of infection. Secondary challenge showed that acquired protective immunity developed in all but class II-/- mice. Vaginal anti-chlamydial IgA antibody coincided with the resolution of infection.
35. Starnbach MN, Bevan MJ, Lampe MF: Protective cytotoxic T lymphocytes are induced during murine infection with Chlamydia trachomatis. J Immunol 1994, 153:5183-5189. See [36**]
36. Starnbach MN, Bevan MJ, Lampe MF: Murine cytotoxic T lymphocytes induced following Chlamydia trachomatis intraperitoneal or genital tract infection respond to cells infected with multiple serovars. Infect Immun 1995, 63:3527-3530. In the previous study [35*], the authors reported the isolation and characterization of a cytotoxic T lymphocyte line from mice following intraperitoneal infection with C. trachomatis serovar L-2 which causes lymphogranuloma venereum in humans. This cell line lysed Chlamydia-infected cells in vitro and showed some protective activity when adoptively transferred into C. trachomatis-infected mice. In this study, they show that a cytotoxic T lymphocyte can also be primed following introduction of C. trachomatis L2 into the uterus and ovarian bursa of mice. Cytotoxic T lymphocyte lines were also isolated following murine infection with typical human urogenital isolates of C. trachomatis from different inoculation sites. These cytotoxic T lymphocyte lines were able to lyse cells infected with C. trachomatis serovars representative of organisms causing trachoma, genital infection and systemic lymphogranuloma venereum.